This failure of PERK inhibition as a cancer therapeutic was expected since both mice and humans with a genetic loss of PERK suffer from rapid β-cell death (Harding et al. 2001; Zhang et al. 2002). The gene discussed is EIF2AK3; the disease is cancer.